New treatments and adverse events impacting patient quality of life were among the topics of interest in 2024.

University of Cincinnati Cancer Center experts will present abstracts at the 66th American Society of Hematology (ASH) Annual ...

Experts discussed the great advances and innovations they’ve seen this year in acute myeloid leukemia (AML) and multiple myeloma.

Novel triple-drug therapies are showing promise for patients with various kinds of leukemia, researchers reported at the ...

Foghorn Therapeutics has finally given up on its only wholly-owned clinical-stage candidate after the troubled cancer drug ...

A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary ...

Study reveals how socioeconomic factors create barriers to bone marrow transplants for AML patients in disadvantaged ...

The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.

Patients with acute myeloid leukemia who have lower education levels and lower income are less likely to receive an ...

(RTTNews) - Moleculin Biotech, Inc. (MBRX), Wednesday announced the preliminary activity of Annamycin in heavily pretreated, relapsed/refractory acute myeloid leukemia or AML patients who had ...